About Translocating chain-associated membrane protein 1
Translocating chain-associated membrane protein 1 (TRAM1) is a protein
from Homo sapiens identified by UniProt accession
Q15629, 374 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | Translocating chain-associated membrane protein 1 |
| UniProt accession | Q15629 |
| Gene | TRAM1 |
| Organism | Homo sapiens |
| Length | 374 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (34)
Diseases linked to this target (Open Targets).
- refractive error · score 0.24
- cardiac troponin T measurement · score 0.21
- age at onset · score 0.19
- Myopia · score 0.19
- Abnormality of refraction · score 0.19
- heel bone mineral density · score 0.18
- refractive error measurement · score 0.16
- bone quantitative ultrasound measurement · score 0.14
- endometrial cancer · score 0.11
- BMI-adjusted waist-hip ratio · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15629-F1 | alphafold | PREDICTED | 83.76 | — |
Amino-acid sequence (374 residues)
MAIRKKSTKS PPVLSHEFVL QNHADIVSCV AMVFLLGLMF EITAKASIIF VTLQYNVTLP ATEEQATESV SLYYYGIKDL ATVFFYMLVA IIIHAVIQEY MLDKINRRMH FSKTKHSKFN ESGQLSAFYL FACVWGTFIL ISENYISDPT ILWRAYPHNL MTFQMKFFYI SQLAYWLHAF PELYFQKTKK EDIPRQLVYI GLYLFHIAGA YLLNLNHLGL VLLVLHYFVE FLFHISRLFY FSNEKYQKGF SLWAVLFVLG RLLTLILSVL TVGFGLARAE NQKLDFSTGN FNVLAVRIAV LASICVTQAF MMWKFINFQL RRWREHSAFQ APAVKKKPTV TKGRSSKKGT ENGVNGTLTS NVADSPRNKK EKSS
Explore Translocating chain-associated membrane protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets